Emergency department antimicrobial considerations in severe sepsis

Emergency Medicine Clinics of North America

Volumn 32, Issue 4, 2014, Pages 835-849

  Green, Robert S ^a   Gorman, Sean K ^b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antimicrobial pharmacodynamics and pharmacokinetics; Antimicrobial shortages; Emergency medicine; Procalcitonin; Severe sepsis; Timing of antimicrobials

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOPENICILLIN; AMPICILLIN; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MEROPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; PROCALCITONIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SIALIDASE INHIBITOR; TOBRAMYCIN; VANCOMYCIN; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; AREA UNDER THE CURVE; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; CRITICALLY ILL PATIENT; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; DRUG CHOICE; DRUG DISTRIBUTION; EMERGENCY CARE; HUMAN; INFLUENZA; KIDNEY FAILURE; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NECROTIZING FASCIITIS; NONHUMAN; PATIENT CARE; PHARMACODYNAMICS; PNEUMOCOCCAL INFECTION; PSEUDOMONAS PNEUMONIA; PYELONEPHRITIS; RECOMMENDED DRUG DOSE; REVIEW; SEPSIS; SEPTIC SHOCK; STREPTOCOCCUS PNEUMONIAE; URINE CULTURE; VOLUME OF DISTRIBUTION; EMERGENCY HEALTH SERVICE; MICROBIOLOGY; PRACTICE GUIDELINE;

ANTI-INFECTIVE AGENTS; BIOLOGICAL MARKERS; DRUG RESISTANCE, MICROBIAL; EMERGENCY SERVICE, HOSPITAL; HUMANS; PRACTICE GUIDELINES AS TOPIC; SEPSIS; SHOCK, SEPTIC;

EID: 84914153482     PISSN: 07338627     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.emc.2014.07.014     Document Type: Review

References (71)

1. Centers for Disease Control and Prevention. National Hospital Ambulatory Medical Care Survey: 2010 Emergency Department summary tables. Available at: Accessed October 15, 2013. http://www.cdc.gov/nchs/data/ahcd/nhamcs_emergency/2010_ed_web_tables.pdf.
2. Dellinger R.P., Levy M.M., Rhodes A., et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013, 41:580-637.
3. Strehlow M.C., Emond S.D., Shapiro N.I., et al. National study of emergency department visits for sepsis, 1992 to 2001. Ann Emerg Med 2006, 48:326-331.
4. Levy M.M., Dellinger R.P., Townsend S.R., et al. The surviving sepsis campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Crit Care Med 2010, 38:367-374.
5. McGregor J.C., Rich S.E., Harris A.D., et al. Asystematic review of the methods used to assess the association between appropriate antibiotic therapy and mortality in bacteremic patients. Clin Infect Dis 2007, 45:329-337.
6. Kollef M.H., Sherman G., Ward S., et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999, 115:462-474.
7. Taccone F.S., Hites M., Beumier M., et al. Appropriate antibiotic dosage levels in the treatment of severe sepsis and septic shock. Curr Infect Dis Rep 2011, 13:406-415.
8. Kumar A., Roberts D., Wood K.E., et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 34:1589-1596.
9. Kumar A., Ellis P., Arabi Y., et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009, 136:1237-1248.
10. Capp R., Chang Y., Brown D.F. Effective antibiotic treatment prescribed by emergency physicians in patients admitted to the intensive care unit with severe sepsis or septic shock: where is the gap?. JEmerg Med 2011, 41:573-580.
11. Green R.S., Djogovic D., Gray S., et al. Canadian Association of Emergency Physicians sepsis guidelines: the optimal management of severe sepsis in Canadian emergency departments. CJEM 2008, 10:443-459.
12. Green R.S., Gorman S.K. Optimizing initial antibiotic delivery for adult patients with severe sepsis and septic shock in the emergency department. EM Critical Care 2012, (Suppl):1-16.
13. Leekha S., Terrell C.L., Edson R.S. General principles of antimicrobial therapy. Mayo Clin Proc 2011, 86:156-167.
14. Brun-Buisson C., Doyon F., Carlet J., et al. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. JAMA 1995, 274:968-974.
15. Johnson M.T., Reichley R., Hoppe-Bauer J., et al. Impact of previous antibiotic therapy on outcome of Gram-negative severe sepsis. Crit Care Med 2011, 39:1859-1865.
16. Mandell L.A., Wunderink R.G., Anzueto A., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44:S27-S72.
17. Wakatake H., Fujitani S., Kodama T., et al. Positive clinical risk factors predict a high rate of methicillin-resistant Staphylococcus aureus colonization in emergency department patients. Am J Infect Control 2012, 40:988-991.
18. Niederman M.S., Craven D.E., Bonten M.J., et al. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171:388-416.
19. Falagas M.E., Karageorgopoulos D.E. Extended-spectrum β-lactamase-producing organisms. JHosp Infect 2009, 73:345-354.
20. Cullen M., Fogg T., Delaney A. Timing of appropriate antibiotics in patients with septic shock: a retrospective cohort study. Emerg Med Australas 2013, 25:308-315.
21. Puskarich M.A., Trzeciak S., Shapiro N.I., et al. Association between timing of antibiotic administration and mortality from septic shock in patients treated with a quantitative resuscitation protocol. Crit Care Med 2011, 39:2066-2071.
22. Marshall J.C., Maier R.V., Jimenez M., et al. Source control in the management of severe sepsis and septic shock: an evidence-based review. Crit Care Med 2004, 32(Suppl 11):S513-S526.
23. Tabah A., Koulenti D., Laupland K., et al. Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT international cohort study. Intensive Care Med 2012, 38:1930-1945.
24. Scaglione F., Paraboni L. Pharmacokinetics/pharmacodynamics of antibacterials in the intensive care unit: setting appropriate dosing regimens. Int J Antimicrob Agents 2008, 32:294-301.
25. Roberts J.A., Kruger P., Paterson D.L., et al. Antibiotic resistance - what's dosing got to do with it?. Crit Care Med 2008, 36:2433-2440.
26. Sanchez Garcia M. Early antibiotic treatment failure. Int J Antimicrob Agents 2009, 34(S3):S14-S19.
27. Eyler R.F., Mueller B.A. Antibiotic dosing in critically ill patients with acute kidney injury. Nat Rev Nephrol 2011, 7:226-235.
28. Varghese J.M., Roberts J.A., Lipman J. Pharmacokinetic and pharmacodynamic issues in the critically ill with severe sepsis and septic shock. Crit Care Clin 2011, 27:19-34.
29. Wang H.E., Shapiro N.I., Angus D., et al. National estimates of severe sepsis in United Stated emergency departments. Crit Care Med 2007, 35:1928-1936.
30. Patel G.W., Roderman N., Gehring H., et al. Assessing the effect of the Surviving Sepsis Campaign treatment guidelines on clinical outcomes in a community hospital. Ann Pharmacother 2010, 44:1733-1738.
31. Nicolau D.P. Optimizing antimicrobial therapy and emerging pathogens. Am J Manag Care 1998, 4(10 Suppl 2):S525-S530.
32. Slavik R.S., Jewesson P.J. Selecting antibacterials for outpatient parenteral antimicrobial therapy: pharmacokinetic-pharmacodynamic considerations. Clin Pharmacokinet 2003, 42:793-817.
33. Pankey G.A., Sabath L.D. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections. Clin Infect Dis 2004, 38:864-870.
34. Levison M.E. Pharmacodynamics of antimicrobial drugs. Infect Dis Clin North Am 2004, 18:451-465.
35. Gonzalez U.S., Spencer J.P. Aminoglycosides: a practical review. Am Fam Physician 1998, 15:1811-1820.
36. Taccone F.S., Laterre P.F., Dugernier T., et al. Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care 2010, 14:R126.
37. Dulhunty J.M., Roberts J.A., Davis J.S., et al. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infect Dis 2013, 56:236-244.
38. Falagas M.E., Tansarli G.S., Ikawa K., et al. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. Clin Infect Dis 2013, 56:272-282.
39. Taccone F.S., Laterre P.F., Spapen H., et al. Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care 2010, 14:R53.
40. Galvez R., Luengo C., Cornejo R., et al. Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity. Int J Antimicrob Agents 2011, 38:146-151.
41. Kashuba A.D., Bertino J.S., Nafziger A.N. Dosing of aminoglycosides to rapidly attain pharmacodynamic goals and hasten therapeutic response by using individualized pharmacokinetic monitoring of patients with pneumonia caused by Gram-negative organisms. Antimicrob Agents Chemother 1998, 42:1842-1844.
42. Garot D., Respaud R., Lanotte P., et al. Population pharmacokinetics of ceftriaxone in critically ill septic patients: a reappraisal. Br J Clin Pharmacol 2011, 72:758-767.
43. Roberts J.A., Kirkpatrick C.M., Roberts M.S., et al. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. JAntimicrob Chemother 2009, 64:142-150.
44. Roberts J.A., Kirkpatrick C.M., Roberts M.S., et al. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Agents 2010, 35:156-163.
45. Gous A., Lipman J., Scribante J., et al. Fluid shifts have no influence on ciprofloxacin pharmacokinetics in intensive care patients with intra-abdominal sepsis. Int J Antimicrob Agents 2005, 26:50-55.
46. Tayab Z.R., Hochhaus G., Kaufmann S., et al. Do intensive care patients need an individualized dosing regimen for levofloxacin?. Int J Clin Pharmacol Ther 2006, 44:262-269.
47. Rybak M., Lomaestro B., Rotschafer J.C., et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009, 66:82-98.
48. Ulldemonlins M., Roberts J.A., Lipman J., et al. Antibiotic dosing in multiple organ dysfunction syndrome. Chest 2011, 139:1210-1220.
49. Strimbu K., Tavel J.A. What are biomarkers?. Curr Opin HIV AIDS 2010, 5:463-466.
50. Pierrakos C., Vincent J.L. Sepsis biomarkers: a review. Crit Care 2010, 14:R15.
51. Vincent J.L., Beumier M. Diagnostic and prognostic markers in sepsis. Expert Rev Anti Infect Ther 2013, 11:265-275.
52. Kruger S., Welte T. Biomarkers in community-acquired pneumonia. Expert Rev Respir Med 2012, 6:203-214.
53. Haubitz S., Mueller B., Schuetz P. Streamlining antibiotic therapy with procalcitonin protocols: consensus and controversies. Expert Rev Respir Med 2013, 7:145-157.
54. Uzzan B., Cohen R., Nicolas P., et al. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med 2006, 34:1996-2003.
55. Tang B.M., Eslick G.D., Craig J.C., et al. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis 2007, 7:210-217.
56. Wacker C., Prkno A., Brunkhorst F.M., et al. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis 2013, 13:426-435.
57. Institute of Medicine Committee to Advise the Public Health Service on Clinical Practice Guidelines. Clinical practice guidelines: direction for a new program 1990, 55-77. National Academy Press, Washington, DC. M.J. Field, K.N. Lohr (Eds.).
58. Gundersen L. The effect of clinical practice guidelines on variations in care. Ann Intern Med 2000, 133:317-318.
59. Dellinger R.P., Carlet J.M., Masur H., et al. Surviving Sepsis Campaign guidelines for the management of severe sepsis and septic shock. Crit Care Med 2004, 32:858-873.
60. Dellinger R.P., Levy M.M., Carlet J.M., et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008, 36:296-327.
61. Gorman S.K., Chung M.H., Slavik R.S., et al. Acritical appraisal of the quality of critical care clinical practice guidelines and their strength of recommendations. Intensive Care Med 2010, 36:1636-1643.
62. Cuthbertson B.H., Campbell M.K., MacLennan G., et al. Clinical stakeholders' opinions on the use of selective decontamination of the digestive tract in critically ill patients in intensive care units: an international Delphi study. Crit Care 2013, 17:R266.
63. Jones A.E., Puskarich M.A. The surviving sepsis campaign guidelines 2012: update for emergency physicians. Ann Emerg Med 2014, 63:35-47.
64. Gupta K., Hooton T.M., Naber K.G., et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011, 52:e103-e120.
65. Fox E.R., Birt A., James K.B., et al. ASHP guidelines on managing drug product shortages in hospitals and health systems. Am J Health Syst Pharm 2009, 66:1399-1406.
66. Griffith M.M., Gross A.E., Sutton S.H., et al. The impact of anti-infective drug shortages on hospitals in the United States: trends and causes. Clin Infect Dis 2012, 54:684-691.
67. Hall R., Bryson G.L., Flowerdew G., et al. Drug shortages in Canadian anesthesia: a national survey. Can J Anaesth 2013, 60:539-551.
68. Kaakeh R., Sweet B.V., Reilly C., et al. Impact of drug shortages on U.S. health systems. Am J Health Syst Pharm 2011, 68:e13-e21.
69. American Society of Health-System Pharmacists (ASHP). Drug Shortages Resource Center. Available at: Accessed November 24, 2013. http://www.ashp.org/drugshortages/current.
70. Griffith M.M., Patel J.A., Sutton S.H., et al. Prospective approach to managing antimicrobial drug shortages. Infect Control Hosp Epidemiol 2012, 33:745-752.
71. Griffith M.M., Pentoney Z., Scheetz M.H. Antimicrobial drug shortages: a crisis amidst the epidemic and the need for antimicrobial stewardship efforts to lessen the effects. Pharmacotherapy 2012, 32:665-667.